Advertisement

Beyond the Differences in Tonsillectomy in IgA Nephropathy: From Rationale To Indications in Patients

  • Yusuke SuzukiEmail author
  • Rosanna Coppo
  • Yasuhiko Tomino
Chapter

Abstract

In the special symposiums on IgA nephropathy (IgAN) (Symposium 3, IgAN Basic; Symposium 4, IgAN Clinical/KDIGO) at the last Asian Pacific Congress of Nephrology (APCN) 2014 in Tokyo, discussion by expert nephrologists from Asian and Western countries revealed how actual clinical practices in IgAN, including timing of renal biopsy and choices of treatments, are different, despite evidence-based guidelines. In particular, indication for tonsillectomy with or without steroid pulse therapy for IgAN patients is markedly different between Asian and European-American practices. The tonsillectomy is considered to be old-fashioned in Western countries, while it is still widely accepted in Asian countries such as Japan and China. The present chapter discusses rationale of tonsillectomy, with up-to-date understanding of IgAN pathogenesis, and summarizes the actual difference in the IgAN practice with respect to tonsillectomy with or without steroid pulse therapy, such as clinical stages at the intervention, based on some key papers from Asian and Western countries. In addition, we attempt to identify the medical and social causes behind these differences.

Keywords

Tonsillectomy Steroid pulse therapy Mucosal immunity Galactose-deficient IgA Randomized clinical trial 

Notes

Acknowledgments

We would like to thank all participants in the special symposiums of IgAN in APCN 2014: Prof. Kawamura T, Yuzawa Y, Narita I, Katafuchi R, Yasuda T, Yasuda Y, Yamamoto R, Hirano K, Goto S, Suzuki H, Li PKT, Liu ZH, Chae DW, Zhang H, Barratt J, Novak J, Coppo R, Mustonen J, Glassock R, the Asian Pacific Society of Nephrology (APSN) president Prof. Harris D, and the president of Japanese Society of Nephrology (JSN) Prof. Matsuo S. We also thank NDT-Educational for the possibility to expand the discussion on tonsillectomy in IgAN refining the material for the preparation of this manuscript.

Conflict of Interest The authors declare that they have no conflict of interest.

References

  1. 1.
    Schena FP, Coppo R. IgA nephropathies. In: Davison AM, Ritz E, Cameron JS, Winearls C, editors. Oxford textbook of clinical nephrology. 3rd ed. Oxford: Oxford University Press; 2005.Google Scholar
  2. 2.
    Béné MC, Hurault de Ligny B, Kessler M, Foliguet B, Faure GC. Tonsils in IgA nephropathy. Contrib Nephrol. 1993;104:153–61.CrossRefPubMedGoogle Scholar
  3. 3.
    Coppo R, D’Amico G. Factors predicting progression of IgA nephropathies. J Nephrol. 2005;18:503–12.PubMedGoogle Scholar
  4. 4.
    Barbour SJ, Reich HN. Risk stratification of patients with IgA nephropathy. Am J Kidney Dis. 2012;59:865–73.CrossRefPubMedGoogle Scholar
  5. 5.
    Suzuki Y, Suzuki H, Yasutake J, Tomino Y. Paradigm shift in activity assessment of IgA nephropathy – optimizing the next generation of diagnostic and therapeutic maneuvers via glycan-targeting. Expert Opin Biol Ther. 2015;20:1–11.Google Scholar
  6. 6.
    Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007;71:159–66.CrossRefPubMedGoogle Scholar
  7. 7.
    Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003;63:1468–74.CrossRefPubMedGoogle Scholar
  8. 8.
    Amore A, Coppo R, Nedrud JG, Sigmund N, Lamm ME, Emancipator SN. The role of nasal tolerance in a model of IgA nephropathy induced in mice by Sendai virus. Clin Immunol. 2004;113:101–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Suzuki H, Suzuki Y, Narita I, Aizawa M, Kihara M, Yamanaka T, et al. Toll-like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol. 2008;19:2384–95.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Kajiyama T, Suzuki Y, Kihara M, Suzuki H, Horikoshi S, Tomino Y. Different pathological roles of toll-like receptor 9 on mucosal B cells and dendritic cells in murine IgA nephropathy. Clin Dev Immunol. 2011;2011:819646.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Wu G, Peng YM, Liu FY, Xu D, Liu C. The role of memory B cell in tonsil and peripheral blood in the clinical progression of IgA nephropathy. Hum Immunol. 2013;74:708–12.CrossRefPubMedGoogle Scholar
  12. 12.
    Novak J, Moldoveanu Z, Julian BA, Raska M, Wyatt RJ, Suzuki Y, et al. Aberrant glycosylation of IgA1 and anti-glycan antibodies in IgA nephropathy: role of mucosal immune system. Adv Otorhinolaryngol. 2011;72:60–3.PubMedGoogle Scholar
  13. 13.
    Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22(10):1795–803.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Horie A, Hiki Y, Odani H, Yasuda Y, Takahashi M, Kato M, et al. IgA1 molecules produced by tonsillar lymphocytes are under-O-glycosylated in IgA nephropathy. Am J Kidney Dis. 2003;42:486–96.CrossRefPubMedGoogle Scholar
  15. 15.
    Inoue T, Sugiyama H, Hiki Y, Takiue K, Morinaga H, Kitagawa M, et al. Differential expression of glycogenes in tonsillar B lymphocytes in association with proteinuria and renal dysfunction in IgA nephropathy. Clin Immunol. 2010;136:447–55.CrossRefPubMedGoogle Scholar
  16. 16.
    Chen X, Liu H, Peng Y, He L, Zhang Y, Xie Y, et al. Expression and correlation analysis of IL-4, IFN-γ and FcαRI in tonsillar mononuclear cells in patients with IgA nephropathy. Cell Immunol. 2014;289(1–2):70–5.CrossRefPubMedGoogle Scholar
  17. 17.
    He L, Peng Y, Liu H, Yin W, Chen X, Peng X, et al. Activation of the interleukin-4/signal transducer and activator of transcription 6 signaling pathway and homeodomain-interacting protein kinase 2 production by tonsillar mononuclear cells in IgA nephropathy. Am J Nephrol. 2013;38(4):321–32.CrossRefPubMedGoogle Scholar
  18. 18.
    Suzuki H, Raska M, Yamada K, Moldoveanu Z, Julian BA, Wyatt RJ, et al. Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes. J Biol Chem. 2014;289:5330–9.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Sato D, Suzuki Y, Kano T, Suzuki H, Matsuoka J, Yokoi H, et al. Tonsillar TLR9 expression and efficacy of tonsillectomy with steroid pulse therapy in IgA nephropathy patients. Nephrol Dial Transplant. 2012;27(3):1090–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Nakata J, Suzuki Y, Suzuki H, Sato D, Kano T, Yanagawa H, et al. Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy. PLoS One. 2014;21:9.Google Scholar
  21. 21.
    Vergano L, Loiacono E, Albera R, Coppo R, Camilla R, Peruzzi L, et al. Can tonsillectomy modify the innate and adaptive immunity pathways involved in IgA nephropathy? J Nephrol. 2015;28(1):51–8.Google Scholar
  22. 22.
    Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014;46:1187–96.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Coppo R. The intestine-renal connection in IgA nephropathy. Nephrol Dial Transplant. 2015;30:360–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Suzuki Y, Tomino Y. The mucosa-bone-marrow axis in IgA nephropathy. Contrib Nephrol. 2007;157:70–9.PubMedGoogle Scholar
  25. 25.
    Nakata J, Suzuki Y, Suzuki H, Sato D, Kano T, Horikoshi S, et al. Experimental evidence of cell dissemination playing a role in pathogenesis of IgA nephropathy in multiple lymphoid organs. Nephrol Dial Transplant. 2013;28:320–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Kawaguchi T, Ieiri N, Yamazaki S, Hayashino Y, Gillespie B, Miyazaki M, et al. Clinical effectiveness of steroid pulse therapy combined with tonsillectomy in patients with immunoglobulin A nephropathy presenting glomerular haematuria and minimal proteinuria. Nephrology. 2010;15:116–23.CrossRefPubMedGoogle Scholar
  27. 27.
    Suzuki Y, Suzuki H, Nakata J, Sato D, Kajiyama T, Watanabe T, et al. Pathological role of tonsillar B cells in IgA nephropathy. Clin Dev Immunol. 2011;2011:639074.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Xie Y, Nishi S, Ueno M, Imai N, Sakatsume M, Narita I, et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int. 2003;63:1861–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Rasche FM, Schwarz A, Keller F. Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin Nephrol. 1999;51:147–52.PubMedGoogle Scholar
  30. 30.
    Piccoli A, Codognotto M, Tabbi MG, Favaro E, Rossi B. Influence of tonsillectomy on the progression of mesangioproliferative glomerulonephritis. Nephrol Dial Transplant. 2010;25:2583–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Chen Y, Tang Z, Wang Q, Yu Y, Zeng C, Chen H, et al. Long-term efficacy of tonsillectomy in Chinese patients with IgA nephropathy. Am J Nephrol. 2007;27:170–5.CrossRefPubMedGoogle Scholar
  32. 32.
    Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–43.CrossRefPubMedGoogle Scholar
  33. 33.
    Miura N, Imai H, Kikuchi S, Hayashi S, Endoh M, Kawamura T, et al. Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy. Clin Exp Nephrol. 2009;13:460–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Sakai K, Saneshige M, Takasu J, Yanagisawa T, Aoki Y, Kawamura T, et al. Clinical remission and pathological progression after tonsillectomy in a renal transplant patient with recurrent IgA nephropathy. Clin Transplant. 2009;23:44–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Kawamura T, Yoshimura M, Miyazaki Y, Okamoto H, Kimura K, Hirano K, et al. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant. 2014;29(8):1546–53.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2012;2:218–20.Google Scholar
  37. 37.
    Matsuzaki K, Suzuki Y, Nakata J, Sakamoto N, Horikoshi S, Kawamura T, et al. Nationwide survey on current treatments for IgA nephropathy in Japan. Clin Exp Nephrol. 2013;17:827–33.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Sugiyama H, Yokoyama H, Sato H, Saito T, Kohda Y, Nishi S, et al. Japan Renal Biopsy Registry and Japan Kidney Disease Registry: committee report for 2009 and 2010. Clin Exp Nephrol. 2013;17:155–73.CrossRefPubMedGoogle Scholar
  39. 39.
    Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide) lines – application to the individual patient. Kidney Int. 2012;82:840–56.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan 2016

Authors and Affiliations

  1. 1.Division of Nephrology, Department of Internal MedicineJuntendo University Faculty of MedicineTokyoJapan
  2. 2.Nephrology, Dialysis and TransplantationRegina Margherita Children’s University HospitalTurinItaly

Personalised recommendations